Vita 34 AG: Successful Annual General Meeting 2014

Leipzig, 28 August 2014 – Vita 34 AG (WKN A0BL84), a pioneer in the storage of stem cells from umbilical cord blood and tissue, and a specialist in cryo-preservation, successfully conducted its Annual General Meeting 2014 today in Leipzig. 32.2 percent of capital stock took advantage of the opportunity to exercise voting rights. Dr. André Gerth, Chairman of the Management Board of this stem cell bank that is market leader in the German-speaking countries gave the past fiscal year a positive review, and he provided insight into the Vita 34 AG growth strategy.

All of the Supervisory Board members and the Management Board in office in fiscal year 2013 were granted discharge within the context of the Annual General Meeting. The Annual General Meeting authorized the Management Board of Vita 34 to issue once or multiple times individually registered, no-par value common stock in exchange for cash or consideration in kind. To this end, authorized capital in the amount of EUR 1,513,250.00 was created (this is equivalent to some 50 percent of the current nominal capital).

Dr. André Gerth outlined the positive development of Vita 34 AG in the past fiscal year to the shareholders. The consistent implementation of the growth strategy is intended to bolster profitability, in this year too, and to secure the success of the company in the medium and long-term: “In 2013 we were successful in increasing profitability significantly, while keeping revenues stable. We see growth opportunities in the coming years, in particular through the expansion of our product range with ‘VitaPlusCord’ [VitaPlusNabelschnur], the continuous expansion of our geographical presence, and the intensification of research activities.” In addition, Dr. Gerth pointed out the future potential for Vita 34 AG to pay dividends: “By eliminating the balance sheet loss in accordance with German commercial law by accessing a capital reserve, we have for the first time created the prerequisites for paying a dividend in the future. This will increase the attractiveness of the Vita 34 shares on the capital markets.”

The detailed voting results can be found at www.vita34group.de in the “Annual General Meeting” section.

Company profile

Vita 34 was founded in 1997 as the first private umbilical cord blood bank in Europe and, as a complete provider, offers collection logistics, preparation and storage of umbilical cord blood and cord tissue. The basis for its successful work is an outstanding position in the technological segment of cryo-preservation. Here, cells and tissue are preserved alive at some -190ºC for long periods of time, and can be used if needed in the context of medical treatment. Parents of more than 106,000 children are already taking advantage of this offering and have provided for their children with a stem cell deposit at Vita 34. To date, 27 therapeutic applications have been performed with stem cell preparations stored at Vita 34.